More News! 13 Nov 2018 French Company’s Drug Lowers Blood Pressure by Targeting Brain Proteins The French company Quantum Genomics is developing a first-in-class drug that targets proteins in the brain to lower blood pressure. A Phase IIb trial, run by Quantum Genomics, found that eight weeks of taking its drug significantly lowered blood pressure in patients who were overweight or obese and with high blood pressure. This reduction also […] November 13, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2018 Solid Phase II Performance for French Autoimmune Liver Disease Drug Genkyotex’s small molecule therapy had encouraging short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial. Over six weeks, the drug reduced the blood levels of a liver disease biomarker molecule by up to 23% in 92 participants. In patients with late-stage disease, who have few treatments available, […] November 7, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Nov 2018 DNA Repair Treatment Shows Early Promise for Treating Cancer Paris-based Onxeo has proved in humans the potential of a cancer treatment that interferes with DNA repair mechanisms. The therapy has potential to work in a wide range of tumors without cancer cells becoming resistant. Onxeo has reported preliminary results from an ongoing Phase I trial in which six different doses will be tested. […] November 5, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2018 15-Minute Cardiovascular Blood Test to Sell Across Europe French diagnostics company Magnisense has raised €5M to expand the sales of its emergency tests for heart attack and heart failure, which can be performed at home in just 15 minutes. The diagnostic technology developed by Magnisense, called MiAG, uses magnetic nanoparticles to detect extremely low quantities of cardiovascular biomarkers in the blood. “MiAG allows […] October 24, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2018 Microbiome Biotech Enterome Signs Deal With Takeda Worth up to €600M The French biotech Enterome and Takeda are teaming up to fight Crohn’s disease, with a deal worth up to €600M. The two companies will collaborate in the development and commercialization of Enterome’s lead microbiome-targeting treatment currently in Phase I trials. Under the terms of the deal, Takeda will pay Enterome €44M upfront, and up to […] October 23, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2018 Innate’s Cancer Immunotherapy Combo Beats Standard Treatment Twofold A combination cancer immunotherapy from French biotech Innate Pharma was twice as effective at treating recurrent squamous cell carcinoma as standard therapy in a Phase II trial. Squamous cell carcinoma is a head and neck cancer that forms lesions in the mucous membranes of body cavities such as the mouth, nose and throat. “Patients are […] October 22, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 16 Oct 2018 Drug Combination for Rare Genetic Nerve Disorder Nails Phase III A treatment developed by French biotech Pharnext has become the first clinically proven therapy for a rare genetic disorder that affects the nervous system. In a Phase III trial, the treatment reduced the level of disability of patients with Charcot-Marie-Tooth disease, a condition that affects peripheral nerves. This disease causes problems with walking, running and […] October 16, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Oct 2018 Slow-Release Drug Biotech IPO Raises €30M The French biotech MedinCell, an injectable slow-release drug specialist, has received a shot of success as its IPO raises €30M in the Euronext stock exchange in Paris. MedinCell is hoping to improve patient compliance with medication regimes by injecting them with a drug-infused gel. Patient compliance with taking medication can be as low as 30% […] October 9, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 25 Sep 2018 How to Overcome Failure as a Biotech Company Turning failure into success is a difficult but much needed skill in a high-risk industry such as biotech. At our latest Labiotech Refresh event, Christine Placet, now the CEO of ophthalmic gene therapy company Horama, shared her personal story of how she saved her previous company, Trophos, from an almost certain failure. The mission of […] September 25, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 19 Sep 2018 This Liver Model Made With 4D Bioprinting Could Improve Drug Toxicity Testing Poietis has partnered with the pharma company Servier to develop a 4D bioprinted liver model that could predict liver toxicity of drugs better than current methods. Liver toxicity testing is one of the key tests that are performed during preclinical trials with investigational drugs. “The role of the liver is to degrade substances toxic to […] September 19, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2018 Update: French Biotech Raises €22M for a Gene Therapy Trial in Retinitis Pigmentosa Update (18/09/2018): Horama has increased the total raised in its Series B fundraising to €22.5M, with the Belgian fund V-Bio Ventures joining the team of investors backing the company. The funds will be mainly directed at developing Horama’s gene therapy for retinitis pigmentosa. Published on 08/10/2017 Horama has raised a second fundraising round that will support […] September 18, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2018 Insulin Combo Reduces After-Meal Sugar Spikes in Type 1 Diabetics In the midst of a legal litigation with Eli Lilly, Adocia has released Phase 1 data showing its insulin combo can outperform Lilly’s fast-acting insulin in keeping sugar levels low after a meal. The trial, which recruited 24 type 1 diabetics, studied the effect of Adocia’s BioChaperone pramlintide insulin on glucose levels right after […] September 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email